DailyIQ
DailyIQ
Last updatedUpdating…

WST·West Pharmaceutical Services, Inc.

$399.86
+7.38 (+1.88%)
After Hours
High
$402.40
Open
$389.62
Market Cap
29.02B
52W High
$438.27
Low
$385.32
P. Close
$399.86
P/E
51.37
52W Low
$223.83
Fwd P/E
38.47
DailyIQ Est.
$490.66
Inst. Own.
79.8%
Short Interest
2.77%
Days to Cover
4.2
Div. Yield
0.22%
Next Ex-Div
~Jan 27
Div. Growth
33+ yrs
NewEarnings release, scored · filed Oct 29, 2026tone -6.5 vs prior release · 61 lines scoredSee the breakdown
Technical Score (1D)
75
BULLISH
News Sentiment
60
BULLISH
On Nov 5, West Pharmaceutical Services (WST) was highlighted as a strong momentum stock by Zacks, citing its Momentum Style Score of A. The article noted that WST’s recent price trend and earnings estimate revisions supported a bullish outlook. Analysts emphasized that momentum investing seeks to capitalize on sustained price movements, and WST’s performance aligned with this strategy. The piece also referenced the complementary role of the Zacks Rank in evaluating the stock’s potential. Overall, the coverage suggested a favorable but not transformative view of WST’s prospects.
LOW TARGET
$340 -15.0%
1 analysts
MEAN TARGET
$471 +17.8%
13 analysts
HIGH TARGET
$500 +25.1%
9 analysts
PRICE RANGE
$340.00 - $500.00
SB / B / H / S / SS
7/13/1/1/1
DAILYIQ EST.
$490.66 (+22.7%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Symbol
WST
Description
West Pharmaceutical Services, Inc. is a global provider of containment and delivery systems for injectable drugs and healthcare products, serving the pharmaceutical industry across multiple continents. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Its Proprietary Products segment focuses on developing and supplying critical components like stoppers, seals, syringes, and advanced drug delivery systems, including innovative solutions like Crystal Zenith. Simultaneously, the Contract-Manufactured Products segment designs and assembles devices for surgical, diagnostic, and drug delivery applications. West Pharmaceutical Services, Inc. distributes its products through a combination of direct sales, distribution networks, and contract agents, solidifying its position as a key partner for pharmaceutical and medical device companies.
Bought (1Y)
0 shares
$0
Sold (1Y)
18,987.446 shares
$6.6M
HAUGEN JANET BRUTSCHEA-
Award/Grant44 shares2026-09-30
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Sell2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,500 shares2026-09-14
81/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
35.9%
Net Margin
16.1%
Revenue CAGR
6.5%
Current Ratio
3.02x
Debt / Equity
0.06x
Return on Equity
15.5%

EPS

EstBeatMiss
$1.37$1.73$2.10$2.46$2.83Q2'25Q3'25Q4'25Q1'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$2.31 - -
Q3'26$2.21$2.66+20.2%
Q1'26$2.05$2.13+3.8%
Q4'25$1.67$2.04+22.1%
Q3'25$1.71$1.96+14.6%
Q2'25$1.54$1.84+19.7%

Revenue

EstBeatMiss
$750M$785M$821M$856M$891MQ2'25Q3'25Q4'25Q1'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$834M - -
Q3'26$834M$875M+4.9%
Q1'26$835M$845M+1.2%
Q4'25$773M$805M+4.1%
Q3'25 - $805M -
Q2'25 - $767M -

Market Data

WST Stock Snapshot

BULLISH75/100
$399.81−$0.05 (0.0%)
Market cap
29.02B
P/E ratio
51.4
Day range
$385.32 – $402.40
News sentiment
60/100 · Bullish
Analyst target
$471.00 (+17.8%)
Consensus
Buy · 23 analysts
52-week range+78.6% off low · -8.8% from high
$223.83$438.27
Price $399.81 DailyIQ Est. $490.66

WST is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into WST?

RICH

At today's price, West Pharmaceutical Services, Inc. needs to grow free cash flow about 26.8% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.79% cost of capital. Over the last five years its revenue has trended at 1.7% a year, so the market is asking for 25.1 percentage points above its own delivered rate. On that basis WST looks priced above what its own growth record supports.

Implied FCF growth
26.8%
Growth trend
1.7%
Growth gap
+25.1 pts
Verdict
RICH
Discount rate (WACC)
7.79%
Beta
0.71

Behaviour On Record

What WST's own history says about today's numbers

Realized volatility (21d)
23.2% 45th pct
Below its peak
-15.2%
vs 200-day average
+26.4%
Up days (1y)
55%

West Pharmaceutical Services, Inc. is currently running 23.2% annualised volatility over the last 21 sessions. Measured against WST's own 13 years of daily returns rather than a market-wide average, that is the 45th percentile — close to its own typical level, against a typical reading of 24.4%.

WST is trading -15.2% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -22.8%, and the deepest was -53.0% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +26.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year WST closed higher on 55% of sessions, and it is currently 1 session into a rising streak.

On November specifically: over 13 years of records, WST finished the month higher 10 of 13 times, with a median return of +3.0% and an average of +3.4%. Its strongest month historically has been June at +4.6% on average, its weakest February at -2.1%.

Overnight risk is measurable too: WST has opened more than 2% away from the prior close in 91 of 3,267 sessions (2.8% of the time), with the largest gaps running +9.1% and -15.7%.

Across the last 3 dated reports on file, WST moved an average of 1.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.0% and a largest of +2.8%.

All figures computed from 3,268 daily closes between 2013-11-08 and 2026-11-06, split-adjusted, recomputed daily. Percentiles are against WST's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of WST's sector?

West Pharmaceutical Services, Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
91

Options Market

What is the options market pricing for WST?

CallsPuts

For West Pharmaceutical Services, Inc.'s nearest expiry (2026-11-20, 13 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.45), with at-the-money implied volatility around 33.9%. The options market is pricing roughly a ±6.7% move by that expiry — a range of about $373.12–$426.50.

Put/call ratio (2026-11-20)
0.45
ATM implied volatility
33.9%
Total open interest
1,280
Expected move by 2026-11-20
±6.7% ($373.12–$426.50)

Analyst Consensus Estimates

What do analysts expect WST to earn?

Analysts expect West Pharmaceutical Services, Inc. to earn $9.49 per share in the fiscal year ending Dec 2026 and $11.32 in the fiscal year ending Dec 2028, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$2.28$2.23 to $2.3212$825M11
Mar 2027$2.35$2.31 to $2.406$859M6
Jun 2027$2.48$2.43 to $2.553~$886M-
Sep 2027$2.64$2.36 to $2.883~$944M-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$9.49$9.40 to $9.8816$3.42B14
Dec 2027$10.32$9.19 to $11.0816$3.62B14
Dec 2028$11.32$10.74 to $12.004~$4.05B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on WST?

Citigroup most recently reiterated its rating on West Pharmaceutical Services, Inc. to Buy on Oct 30, 2026 with a price target of $494 (from $412). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Citigroup: Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 30, 2026CitigroupMaintainedBuy$412 → $494
Oct 30, 2026TD CowenMaintainedBuy$420 → $500
Oct 30, 2026BarclaysMaintainedOverweight$440 → $500
Oct 30, 2026Evercore ISI GroupMaintainedOutperform$440 → $480
Oct 13, 2026TD CowenMaintainedBuy$410 → $420
Oct 7, 2026BarclaysMaintainedOverweight$400 → $440
Sep 22, 2026Morgan StanleyUpgradeEqual-Weight → Overweight$365 → $400
Sep 9, 2026UBSMaintainedBuy$340 → $415
Aug 3, 2026CitigroupMaintainedBuy$400 → $412
Jul 27, 2026Evercore ISI GroupMaintainedOutperform$410 → $425
Jul 13, 2026BNP ParibasInitiatedOutperform$447
Jul 9, 2026Morgan StanleyMaintainedEqual-Weight$325 → $365

Earnings Release, Scored

What did West Pharmaceutical Services, Inc.'s latest earnings release say?

Filed Oct 29, 2026 · SEC Form 8-K, Exhibit 99

Tone66.9/ 100-6.5 vs prior release
Hedging words0.20per 100 words-0.28 vs prior release
Tone, last 3 releasesScale 50–83

Most important lines

  1. 1

    The Company repurchased $231 million of stock in the quarter, bringing the year-to-date total to $685 million.

    New this quarter
  2. 2

    Net sales of $145.7 million decreased by 7.3% and declined 6.6% on an organic basis.

    New this quarterNegative tone
  3. 3

    The Company also announced on October 19, 2026, that its Board of Directors declared a fourth-quarter dividend of $0.26 per share, an increase of 18% over the $0.22 per share paid in the prior quarter.

    New this quarter

Peers & ETF holders

WST peers & ETF holders

News & sentiment

What is the news saying about WST?

WST rose 7.4% over the month to Nov 6. News tone held between 53 and 100 from Oct 6 to Oct 15, then dropped to 42 on Oct 19.

Daily close and news tone, Oct 6 to Nov 6
$375$400Oct 6: tone 89Oct 7: tone 80Oct 8: tone 53Oct 9: tone 96Oct 12Oct 13: tone 57Oct 14Oct 15: tone 100Oct 16Oct 19: tone 42Oct 20Oct 21: tone 94Oct 22Oct 23Oct 26Oct 27: tone 57Oct 28: tone 69Oct 29: tone 71Oct 30: tone 71Nov 2: tone 72Nov 3Nov 4: tone 50Nov 5: tone 68Nov 6Oct 6News toneNov 6123
  1. Oct 15 +2.2%same day: West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
  2. Oct 29 +3.2%same day: West (WST) Stock Could Be 28% Overvalued As Cash Flow Falls Short
  3. Nov 5 -4.0%same day: West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?

Technical analysis

How strong is WST's momentum right now?

On the daily chart WST ranks at the 75th percentile for momentum against 1,060 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling WST?

92 of the 196 tracked managers added to WST in their latest 13F and 101 trimmed. Together they own 79.8% of the company, worth $20.4B. BlackRock and Vanguard Capital Management alone hold 15.5%.

92adding101trimming3unchanged
Largest holders by stake, latest 13FBar = share of WST
  1. $2.4B positionTrimmed 2.7% last quarter
  2. $1.7B positionTrimmed 1.5% last quarter
  3. $1.4B positionTrimmed 1.9% last quarter
  4. $1.3B positionAdded 186.0% last quarter
  5. $1.2B positionAdded 1.7% last quarter
  6. $865.8M positionTrimmed 9.3% last quarter
  7. $715.2M positionAdded 1.7% last quarter
  8. $644.7M positionTrimmed 14.9% last quarter
  9. $568.1M positionAdded 8.5% last quarter
  10. $71.0M positionAdded 1.4M shares last quarter
Full holdings history

Congressional trading

Is Congress trading WST?

5 members of Congress disclosed 8 WST trades between Feb 13, 2015 and Jul 22, 2025: 3 buys and 5 sells, about $64.0K in estimated value.

BuysSells20162018202020222024
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has WST done against its peers?

Over the six months to Nov 6, WST returned +27.9%. Of the 15 related stocks and ETFs, 4 did better, led by BDX at +44.6%.

Change since May 6, through Nov 6
−40%−20%0%+20%+40%+60%May 6JunJulAugSepOctNov 6BDX +44.6%WST +27.9%BSX −23.7%